Form 4: BioCryst Pharmaceuticals Director Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
A BioCryst Pharmaceuticals director, Nancy J. Hutson, sold 7,000 shares of common stock to cover tax liabilities related to vesting restricted stock units.
Summary
- Nancy J. Hutson, a director at BioCryst Pharmaceuticals, sold 7,000 shares of common stock on December 13, 2024.
- The sale was executed at a weighted average price of $7.54 per share.
- The shares were sold to cover tax obligations arising from the vesting of 16,745 restricted stock units.
- The sale was conducted automatically under a pre-arranged trading plan adopted on June 18, 2024, in accordance with Rule 10b5-1.
- Following the transaction, Ms. Hutson beneficially owns 86,638 shares of BioCryst common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction by a company director to cover tax obligations. It is neither particularly positive nor negative for the company's outlook.
Risks
- Sales by insiders can sometimes be perceived negatively by the market, although this sale was for tax purposes and pre-planned.
Industry Context
This is a routine transaction for corporate insiders, particularly when covering tax obligations related to equity compensation. It is common for executives and directors to use 10b5-1 plans to avoid accusations of insider trading.
Comparison to Industry Standards
- Sales by insiders are a common occurrence in publicly traded companies, especially around vesting periods for equity compensation.
- The use of a 10b5-1 trading plan is a standard practice to ensure compliance with insider trading regulations.
- Other pharmaceutical companies will have similar insider trading activity, with directors and executives selling shares for various reasons, including tax obligations.
Stakeholder Impact
- The sale of shares by a director may have a minor impact on shareholder sentiment, but the pre-planned nature of the sale should mitigate any negative perception.
Key Dates
| Date | Description |
|---|---|
| 2024-06-18 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2024-12-13 | Date of the stock sale transaction. |
| 2024-12-16 | Date the Form 4 was signed. |
Keywords
BioCryst Pharmaceuticals, insider trading, stock sale, Form 4, Nancy J. Hutson, Rule 10b5-1, tax liability, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.